Cholesterol: A novel regulatory role in myelin formation

Neuroscientist

Volumn 17, Issue 1, 2011, Pages 79-93

  Saher, Gesine ^a   Quintes, Susanne ^a,b   Nave, Klaus Armin ^a  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cholesterol; ER exist; myelin; oligodendrocyte; Schwann cell

Indexed keywords

7 DEHYDROCHOLESTEROL; CERAMIDE GLUCOSYLTRANSFERASE; CHOLESTEROL; CUPRIZONE; DESMOSTEROL; GALACTOSYLCERAMIDE; MEVINOLIN; MYELIN; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN BASIC PROTEIN; PERIPHERAL MYELIN PROTEIN 22; PROTEOLIPID PROTEIN; SIMVASTATIN; SULFATIDE;

AUTISM; BEHAVIOR DISORDER; BIOGENESIS; CELL DEATH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CHOLESTEROL SYNTHESIS; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; HUMAN; INTRACELLULAR TRANSPORT; LIPID COMPOSITION; MENTAL DEFICIENCY; MICROCEPHALY; MYELINATION; NIEMANN PICK DISEASE; NONHUMAN; OLIGODENDROGLIA; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; SMITH LEMLI OPITZ SYNDROME;

ANIMALS; AXONS; CHOLESTEROL; HUMANS; MYELIN SHEATH; OLIGODENDROGLIA; SCHWANN CELLS;

EID: 79952160968     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858410373835     Document Type: Review

References (121)

1. Adlkofer K., Martini R., Aguzzi A., Zielasek J., Toyka KV, Suter U. 1995. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet 3: 274-80.
2. Agrawal D., Hawk R., Avila RL, Inouye H., Kirschner DA 2009. Internodal myelination during development quantitated using X-ray diffraction. J Struct Biol 3: 521-6.
3. Amici SA, Dunn WA Jr, Murphy AJ, Adams NC, Gale NW, Valenzuela DM, and others. 2006. Peripheral myelin protein 22 is in complex with alpha6beta4 integrin, and its absence alters the Schwann cell basal lamina. J Neurosci 4: 1179-89. (Pubitemid 43237051)
4. Ando S., Tanaka Y., Toyoda Y., Kon K. 2003. Turnover of myelin lipids in aging brain. Neurochem Res 1: 5-13. (Pubitemid 36173222)
5. Banik NL, Davison AN 1971. Exchange of sterols between myelin and other membranes of developing rat brain. Biochem J 5: 751-8.
6. Barrantes FJ 2007. Cholesterol effects on nicotinic acetylcholine receptor. J Neurochem 72-80.
7. Berciano MT, Calle E., Fernandez R., Lafarga M. 1998. Regulation of Schwann cell numbers in tellurium-induced neuropathy: apoptosis, supernumerary cells and internodal shortening. Acta Neuropathol (Berl) 3: 269-79. (Pubitemid 28120672)
8. Birnbaum G., Cree B., Altafullah I., Zinser M., Reder AT 2008. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 18: 1390-5.
9. Björkhem I., Meaney S. 2004. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 5: 806-15. (Pubitemid 38620856)
10. Boggs JM 2006. Myelin basic protein: a multifunctional protein. Cell Mol Life Sci 17: 1945-61. (Pubitemid 44359737)
11. Bosio A., Binczek E., Stoffel W. 1996. Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc Natl Acad Sci U S A 23: 13280-5. (Pubitemid 26382807)
12. Bosse F., Hasse B., Pippirs U., Greiner-Petter R., Muller HW 2003. Proteolipid plasmolipin: localization in polarized cells, regulated expression and lipid raft association in CNS and PNS myelin. J Neurochem 2: 508-18. (Pubitemid 36842450)
13. Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, Weisgraber KH, and others. 1989. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 3: 1015-31. (Pubitemid 19080637)
14. Brophy PJ, Horvath LI, Marsh D. 1984. Stoichiometry and specificity of lipid-protein interaction with myelin proteolipid protein studied by spin-label electron spin resonance. Biochemistry 5: 860-5.
15. Brown DA, London E. 2000. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 23: 17221-4. (Pubitemid 30430750)
16. Bu G. 2009. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 5: 333-44.
17. Bukelis I., Porter FD, Zimmerman AW, Tierney E. 2007. Smith-Lemli-Opitz syndrome and autism spectrum disorder. Am J Psychiatry 11: 1655-61. (Pubitemid 350205340)
18. Burger K., Gimpl G., Fahrenholz F. 2000. Regulation of receptor function by cholesterol. Cell Mol Life Sci 11: 1577-92.
19. Coetzee T., Fujita N., Dupree J., Shi R., Blight A., Suzuki K., and others. 1996. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 2: 209-19. (Pubitemid 26286104)
20. de Vries H., Hoekstra D. 2000. On the biogenesis of the myelin sheath: cognate polarized trafficking pathways in oligodendrocytes. Glycoconj J 3-4: 181-90. (Pubitemid 32055904)
21. Derry JM, Gormally E., Means GD, Zhao W., Meindl A., Kelley RI, and others. 1999. Mutations in a delta 8-delta 7 sterol isomerase in the tattered mouse and X-linked dominant chondrodysplasia punctata. Nat Genet 3: 286-90. (Pubitemid 29297257)
22. Dietschy JM 2009. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem 4: 287-93.
23. Dietschy JM, Turley SD 2004. Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 8: 1375-97. (Pubitemid 39022664)
24. Drenth JP, Cuisset L., Grateau G., Vasseur C., van de Velde-Visser SD, de Jong JG, and others. 1999. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 2: 178-81. (Pubitemid 29264814)
25. Dupree JL, Coetzee T., Blight A., Suzuki K., Popko B. 1998. Myelin galactolipids are essential for proper node of Ranvier formation in the CNS. J Neurosci 5: 1642-9. (Pubitemid 28103072)
26. Dupree JL, Girault JA, Popko B. 1999. Axo-glial interactions regulate the localization of axonal paranodal proteins. J Cell Biol 6: 1145-52.
27. Eckhardt M. 2008. The role and metabolism of sulfatide in the nervous system. Mol Neurobiol 2-3: 93-103.
28. Eggeling C., Ringemann C., Medda R., Schwarzmann G., Sandhoff K., Polyakova S., and others. 2009. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. Nature 7233: 1159-62.
29. Epand RM 2006. Cholesterol and the interaction of proteins with membrane domains. Prog Lipid Res 4: 279-94. (Pubitemid 43818129)
30. Erne B., Sansano S., Frank M., Schaeren-Wiemers N. 2002. Rafts in adult peripheral nerve myelin contain major structural myelin proteins and myelin and lymphocyte protein (MAL) and CD59 as specific markers. J Neurochem 3: 550-62. (Pubitemid 34831494)
31. Fitzky BU, Witsch-Baumgartner M., Erdel M., Lee JN, Paik YK, Glossmann H., and others. 1998. Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. Proc Natl Acad Sci U S A 14: 8181-6.
32. Fitzner D., Schneider A., Kippert A., Mobius W., Willig KI, Hell SW, and others. 2006. Myelin basic protein-dependent plasma membrane reorganization in the formation of myelin. EMBO J 21: 5037-48. (Pubitemid 44658522)
33. Fu Q., Goodrum JF, Hayes C., Hostettler JD, Toews AD, Morell P. 1998. Control of cholesterol biosynthesis in Schwann cells. J Neurochem 2: 549-55. (Pubitemid 28480401)
34. Gaylor JL 2002. Membrane-bound enzymes of cholesterol synthesis from lanosterol. Biochem Biophys Res Commun 5: 1139-46. (Pubitemid 34681085)
35. Gee JR, Keller JN 2005. Astrocytes: regulation of brain homeostasis via apolipoprotein E. Int J Biochem Cell Biol 6: 1145-50. (Pubitemid 40381190)
36. Genden EM, Watanabe O., Mackinnon SE, Hunter DA, Strasberg SR 2002. Peripheral nerve regeneration in the apolipoprotein-E-deficient mouse. J Reconstr Microsurg 6: 495-502.
37. German DC, Liang CL, Song T., Yazdani U., Xie C., Dietschy JM 2002. Neurodegeneration in the Niemann-Pick C mouse: glial involvement. Neuroscience 3: 437-50. (Pubitemid 34121996)
38. Giese KP, Martini R., Lemke G., Soriano P., Schachner M. 1992. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 4: 565-76.
39. Goldstein JL, Brown MS 1990. Regulation of the mevalonate pathway. Nature 6257: 425-30.
40. Goodrum JF, Bouldin TW, Zhang SH, Maeda N., Popko B. 1995. Nerve regeneration and cholesterol reutilization occur in the absence of apolipoproteins E and A-I in mice. J Neurochem 1: 408-16.
41. Goodrum JF, Fowler KA, Hostettler JD, Toews AD 2000. Peripheral nerve regeneration and cholesterol reutilization are normal in the low-density lipoprotein receptor knockout mouse. J Neurosci Res 4: 581-6. (Pubitemid 30090586)
42. Greenwood J., Steinman L., Zamvil SS 2006. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 5: 358-70.
43. Griffiths I., Klugmann M., Anderson T., Yool D., Thomson C., Schwab MH, and others. 1998. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 5369: 1610-3. (Pubitemid 28278256)
44. Guerrero I., Chiang C. 2007. A conserved mechanism of Hedgehog gradient formation by lipid modifications. Trends Cell Biol 1: 1-5. (Pubitemid 46027586)
45. Hanzal-Bayer MF, Hancock JF 2007. Lipid rafts and membrane traffic. FEBS Lett 11: 2098-104. (Pubitemid 46709907)
46. Herz J., Chen Y. 2006. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci 11: 850-9. (Pubitemid 44624177)
47. Honke K., Hirahara Y., Dupree J., Suzuki K., Popko B., Fukushima K., and others. 2002. Paranodal junction formation and spermatogenesis require sulfoglycolipids. Proc Natl Acad Sci U S A 7: 4227-32. (Pubitemid 34285968)
48. Houten SM, Kuis W., Duran M., de Koning TJ, van Royen-Kerkhof A., Romeijn GJ, and others. 1999. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 2: 175-7. (Pubitemid 29264813)
49. Huang X., Litingtung Y., Chiang C. 2007. Region-specific requirement for cholesterol modification of sonic hedgehog in patterning the telencephalon and spinal cord. Development 11: 2095-105. (Pubitemid 46979796)
50. Ikonen E. 2008. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 2: 125-38. (Pubitemid 351158918)
51. Jaegle M., Mandemakers W., Broos L., Zwart R., Karis A., Visser P., and others. 1996. The POU factor Oct-6 and Schwann cell differentiation. Science 5274: 507-10. (Pubitemid 26286453)
52. Jahn O., Tenzer S., Werner HB 2009. Myelin proteomics: molecular anatomy of an insulating sheath. Mol Neurobiol 1: 55-72.
53. Karten B., Peake KB, Vance JE 2009. Mechanisms and consequences of impaired lipid trafficking in Niemann-Pick type C1-deficient mammalian cells. Biochim Biophys Acta 7: 659-70.
54. Kelm S., Pelz A., Schauer R., Filbin MT, Tang S., de Bellard ME, and others. 1994. Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr Biol 11: 965-72. (Pubitemid 124001032)
55. Klopfleisch S., Merkler D., Schmitz M., Kloppner S., Schedensack M., Jeserich G., and others. 2008. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci 50: 13609-14.
56. Klugmann M., Schwab MH, Puhlhofer A., Schneider A., Zimmermann F., Griffiths IR, and others. 1997. Assembly of CNS myelin in the absence of proteolipid protein. Neuron 1: 59-70. (Pubitemid 27053830)
57. Koch S., Donarski N., Goetze K., Kreckel M., Stuerenburg HJ, Buhmann C., and others. 2001. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 7: 1143-51. (Pubitemid 32645797)
58. Konig A., Happle R., Bornholdt D., Engel H., Grzeschik KH 2000. Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid dehydrogenase, cause CHILD syndrome. Am J Med Genet 4: 339-46. (Pubitemid 30084263)
59. Kramer EM, Schardt A., Nave KA 2001. Membrane traffic in myelinating oligodendrocytes. Microsc Res Tech 6: 656-71. (Pubitemid 32222193)
60. Lanzillo R., Orefice G., Quarantelli M., Rinaldi C., Prinster A., Ventrella G., and others. 2010. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 4: 450-4.
61. Le N., Nagarajan R., Wang JY, Svaren J., LaPash C., Araki T., and others. 2005. Nab proteins are essential for peripheral nervous system myelination. Nat Neurosci 7: 932-40.
62. Lee AG 2001. Myelin: delivery by raft. Curr Biol 2: R60-2. Lowry RB, Yong SL 1980. Borderline normal intelligence in the Smith-Lemli-Opitz (RSH) syndrome. Am J Med Genet 2: 137-43.
63. Luccarini I., Ballerini C., Biagioli T., Biamonte F., Bellucci A., Rosi MC, and others. 2008. Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp Neurol 1: 214-26.
64. Marcos J., Shackleton CH, Buddhikot MM, Porter FD, Watson GL 2007. Cholesterol biosynthesis from birth to adulthood in a mouse model for 7-dehydrosterol reductase deficiency (Smith-Lemli-Opitz syndrome). Steroids 11-12: 802-8. (Pubitemid 47320712)
65. Marcus J., Honigbaum S., Shroff S., Honke K., Rosenbluth J., Dupree JL 2006. Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia 4: 372-81.
66. Martini R., Mohajeri MH, Kasper S., Giese KP, Schachner M. 1995. Mice doubly deficient in the genes for P0 and myelin basic protein show that both proteins contribute to the formation of the major dense line in peripheral nerve myelin. J Neurosci 6: 4488-95.
67. Matsuda M., Korn BS, Hammer RE, Moon YA, Komuro R., Horton JD, and others. 2001. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev 10: 1206-16. (Pubitemid 32472750)
68. McGee AW, Strittmatter SM 2003. The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. Trends Neurosci 4: 193-8. (Pubitemid 36412001)
69. Meske V., Albert F., Richter D., Schwarze J., Ohm TG 2003. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur J Neurosci 1: 93-102. (Pubitemid 36098879)
70. Miron VE, Zehntner SP, Kuhlmann T., Ludwin SK, Owens T., Kennedy TE, and others. 2009. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol 5: 1880-90.
71. Morell P., Jurevics H. 1996. Origin of cholesterol in myelin. Neurochem Res 4: 463-70. (Pubitemid 26159264)
72. Muse ED, Jurevics H., Toews AD, Matsushima GK, Morell P. 2001. Parameters related to lipid metabolism as markers of myelination in mouse brain. J Neurochem 1: 77-86. (Pubitemid 32044370)
73. Musse AA, Gao W., Rangaraj G., Boggs JM, Harauz G. 2009. Myelin basic protein codistributes with other PI(4,5) P2-sequestering proteins in Triton X-100 detergent-resistant membrane microdomains. Neurosci Lett 1: 32-6.
74. Nave KA 2010. Myelination and the glial support of long axons. Nat Rev Neurosci 4: 275-283.
75. Nawaz S., Kippert A., Saab AS, Werner HB, Lang T., Nave KA, and others. 2009. Phosphatidylinositol 4,5-bisphosphatedependent interaction of myelin basic protein with the plasma membrane in oligodendroglial cells and its rapid perturbation by elevated calcium. J Neurosci 15: 4794-807.
76. Norton WT, Cammer W. 1984. Isolation and characterization of myelin. In: Morell P, editor. Myelin. New York: Plenum. p 147-95.
77. Nwokoro NA, Wassif CA, Porter FD 2001. Genetic disorders of cholesterol biosynthesis in mice and humans. Mol Genet Metab 1-2: 105-19. (Pubitemid 32955152)
78. Ohashi K., Osuga J., Tozawa R., Kitamine T., Yagyu H., Sekiya M., and others. 2003. Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3methylglutaryl-CoA reductase gene. J Biol Chem 44: 42936-41. (Pubitemid 37345905)
79. Paintlia AS, Paintlia MK, Khan M., Vollmer T., Singh AK, Singh I. 2005. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J 11: 1407-21. (Pubitemid 41278999)
80. Paintlia AS, Paintlia MK, Singh I., Skoff RB, Singh AK 2009. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 2: 182-93.
81. Palmeri S., Battisti C., Federico A., Guazzi GC 1994. Hypoplasia of the corpus callosum in Niemann-Pick type C disease. Neuroradiology 1: 20-2. (Pubitemid 24001249)
82. Paul F., Waiczies S., Wuerfel J., Bellmann-Strobl J., Dorr J., Waiczies H., and others. 2008. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 4: e1928.
83. Pertusa M., Morenilla-Palao C., Carteron C., Viana F., Cabedo H. 2007. Transcriptional control of cholesterol biosynthesis in Schwann cells by axonal neuregulin 1. J Biol Chem 39: 28768-28778. (Pubitemid 47606069)
84. Pfrieger FW 2003. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes ? Bioessays 1: 72-8. (Pubitemid 36093328)
85. Pitas RE, Boyles JK, Lee SH, Foss D., Mahley RW 1987. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1: 148-61. (Pubitemid 17231059)
86. Popko B., Puckett C., Lai E., Shine HD, Readhead C., Takahashi N., and others. 1987. Myelin deficient mice: expression of myelin basic protein and generation of mice with varying levels of myelin. Cell 4: 713-21. (Pubitemid 18096948)
87. Quan G., Xie C., Dietschy JM, Turley SD 2003. Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Brain Res Dev Brain Res 1-2: 87-98. (Pubitemid 37474113)
88. Quarles RH, Macklin WB, Morell P. 2006. Myelin formation, structure, and biochemistry. In: Siegel G, Albers RW, Brady S, Price D, editors. Basic neurochemistry: molecular, cellular, and medical aspects. Burlington, MA: Elsevier. p. 51-72.
89. Readhead C., Popko B., Takahashi N., Shine HD, Saavedra RA, Sidman RL, and others. 1987. Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype. Cell 4: 703-12. (Pubitemid 18096947)
90. Roach A., Takahashi N., Pravtcheva D., Ruddle F., Hood L. 1985. Chromosomal mapping of mouse myelin basic protein gene and structure and transcription of the partially deleted gene in shiverer mutant mice. Cell 1: 149-55. (Pubitemid 16237565)
91. Rogers JT, Weeber EJ 2008. Reelin and apoE actions on signal transduction, synaptic function and memory formation. Neuron Glia Biol 3: 259-70.
92. Rosenbluth J., Nave KA, Mierzwa A., Schiff R. 2006. Subtle myelin defects in PLP-null mice. Glia 3: 172-82. (Pubitemid 44230854)
93. Ryan AK, Bartlett K., Clayton P., Eaton S., Mills L., Donnai D., and others. 1998. Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype. J Med Genet 7: 558-65. (Pubitemid 28302277)
94. Saadat L., Dupree JL, Kilkus J., Han X., Traka M., Proia RL, and others. 2010. Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGT-deficient mice. Glia 58: 391-8.
95. Saher G., Brügger B., Lappe-Siefke C., Möbius W., Tozawa R., Wehr MC, and others. 2005. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 4: 468-75. (Pubitemid 41007564)
96. Saher G., Quintes S., Möbius W., Wehr MC, Kramer-Albers EM, Brügger B., and others. 2009. Cholesterol regulates the endoplasmic reticulum exit of the major membrane protein P0 required for peripheral myelin compaction. J Neurosci 19: 6094-104.
97. Saher G., Simons M. 2010. Cholesterol and myelin biogenesis. In: Harris JR, editor. Cholesterol binding and cholesterol transport proteins: structure and function in health and disease. New York: Springer.
98. Salzer JL, Brophy PJ, Peles E. 2008. Molecular domains of myelinated axons in the peripheral nervous system. Glia 14: 1532-40.
99. Schnaar RL, Lopez PH 2009. Myelin-associated glycoprotein and its axonal receptors. J Neurosci Res 15: 3267-76.
100. Sena A., Pedrosa R., Graca MM 2003. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol 6: 754-5. (Pubitemid 36718367)
101. Shy ME, Jani A., Krajewski K., Grandis M., Lewis RA, Li J., and others. 2004. Phenotypic clustering in MPZ mutations. Brain Pt 2: 371-84. (Pubitemid 38160322)
102. Simons K., Ikonen E. 1997. Functional rafts in cell membranes. Nature 6633: 569-72. (Pubitemid 27248754)
103. Simons M., Kramer EM, Macchi P., Rathke-Hartlieb S., Trotter J., Nave KA, and others. 2002. Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus-Merzbacher disease. J Cell Biol 2: 327-36. (Pubitemid 34839828)
104. Simons M., Kramer EM, Thiele C., Stoffel W., Trotter J. 2000. Assembly of myelin by association of proteolipid protein with cholesterol- and galactosylceramide-rich membrane domains. J Cell Biol 1: 143-54.
105. Stuve O., Youssef S., Weber MS, Nessler S., von Budingen HC, Hemmer B., and others. 2006. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 4: 1037-44.
106. Toews AD, Roe EB, Goodrum JF, Bouldin TW, Weaver J., Goines ND, and others. 1997. Tellurium causes dose-dependent coordinate down-regulation of myelin gene expression. Brain Res Mol Brain Res 1-2: 113-9. (Pubitemid 27453121)
107. Topilko P., Schneider-Maunoury S., Levi G., Baron-Van EA, Chennoufi AB, Seitanidou T., and others. 1994. Krox-20 controls myelination in the peripheral nervous system. Nature 6500: 796-9. (Pubitemid 24333867)
108. Tozawa R., Ishibashi S., Osuga J., Yagyu H., Oka T., Chen Z., and others. 1999. Embryonic lethality and defective neural tube closure in mice lacking squalene synthase. J Biol Chem 43: 30843-8. Uchihara T., Duyckaerts C., He Y., Kobayashi K., Seilhean D., Amouyel P., and others. 1995. ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. Neurosci Lett 1: 5-8.
109. van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL 2009. Statins: mechanisms of neuroprotection. Prog Neurobiol 1: 64-75.
110. Vanier MT, Millat G. 2003. Niemann-Pick disease type C. Clin Genet 4: 269-81. (Pubitemid 37236127)
111. Verheijen MH, Camargo N., Verdier V., Nadra K., de Preux Charles AS, Medard JJ, and others. 2009. SCAP is required for timely and proper myelin membrane synthesis. Proc Natl Acad Sci U S A 50: 21383-8.
112. Verheijen MH, Chrast R., Burrola P., Lemke G. 2003. Local regulation of fat metabolism in peripheral nerves. Genes Dev 19: 2450-64. (Pubitemid 37214792)
113. Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., Markovic-Plese S., and others. 2004. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 9421: 1607-8. (Pubitemid 38625664)
114. Wassif CA, Maslen C., Kachilele-Linjewile S., Lin D., Linck LM, Connor WE, and others. 1998. Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome. Am J Hum Genet 1: 55-62. (Pubitemid 30428318)
115. Waterham HR 2006. Defects of cholesterol biosynthesis. FEBS Lett 23: 5442-9. (Pubitemid 44479759)
116. Waterham HR, Koster J., Mooyer P., Noort GG, Kelley RI, Wilcox WR, and others. 2003. Autosomal recessive HEM/ Greenberg skeletal dysplasia is caused by 3 beta-hydroxysterol delta 14-reductase deficiency due to mutations in the lamin B receptor gene. Am J Hum Genet 4: 1013-7. (Pubitemid 36403319)
117. Waterham HR, Koster J., Romeijn GJ, Hennekam RC, Vreken P., Andersson HC, and others. 2001. Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 4: 685-94. (Pubitemid 32868514)
118. Weber MS, Zamvil SS 2008. Statins and demyelination. Curr Top Microbiol Immunol 313-24.
119. Wechsler A., Brafman A., Shafir M., Heverin M., Gottlieb H., Damari G., and others. 2003. Generation of viable cholesterol-free mice. Science 5653: 2087. (Pubitemid 38017934)
120. Weintraub H., Abramovici A., Sandbank U., Booth AD, Pentchev PG, Sela B. 1987. Dysmyelination in NCTRBalb/C mouse mutant with a lysosomal storage disorder: morphological survey. Acta Neuropathol 4: 374-81. (Pubitemid 17152804)
121. Zhao S., Hu X., Park J., Zhu Y., Zhu Q, Li H, and others. 2007. Selective expression of LDLR and VLDLR in myelinating oligodendrocytes. Dev Dyn 9: 2708-12. (Pubitemid 47450961)